Exelixis (NASDAQ:EXEL)‘s stock had its “hold” rating reiterated by equities research analysts at Oppenheimer in a research report issued to clients and investors on Tuesday.

EXEL has been the topic of a number of other reports. Needham & Company LLC restated a “buy” rating and issued a $30.00 price objective (up from $28.00) on shares of Exelixis in a research note on Tuesday, September 12th. Cann restated a “hold” rating on shares of Exelixis in a research note on Monday, October 16th. Royal Bank of Canada assumed coverage on shares of Exelixis in a research note on Thursday, September 14th. They issued an “outperform” rating and a $32.00 price objective on the stock. Leerink Swann lowered shares of Exelixis from an “outperform” rating to a “market perform” rating and dropped their price objective for the company from $34.00 to $28.00 in a research note on Friday, September 22nd. Finally, Zacks Investment Research upgraded shares of Exelixis from a “hold” rating to a “buy” rating and set a $32.00 price objective on the stock in a research note on Wednesday, October 18th. Six research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Exelixis currently has an average rating of “Buy” and an average target price of $31.38.

Shares of Exelixis (EXEL) opened at $26.68 on Tuesday. Exelixis has a one year low of $14.22 and a one year high of $32.50. The company has a market cap of $7,712.89, a price-to-earnings ratio of 51.12, a P/E/G ratio of 1.17 and a beta of 1.89.

Exelixis (NASDAQ:EXEL) last posted its quarterly earnings data on Wednesday, November 1st. The biotechnology company reported $0.26 EPS for the quarter, beating analysts’ consensus estimates of $0.08 by $0.18. The company had revenue of $152.50 million for the quarter, compared to analyst estimates of $104.91 million. Exelixis had a net margin of 36.80% and a return on equity of 105.47%. Exelixis’s quarterly revenue was up 145.2% on a year-over-year basis. During the same period in the previous year, the business posted ($0.04) earnings per share. research analysts expect that Exelixis will post 0.49 EPS for the current year.

In other news, EVP Jeffrey Hessekiel sold 27,302 shares of the business’s stock in a transaction dated Thursday, September 28th. The shares were sold at an average price of $24.28, for a total transaction of $662,892.56. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Stelios Papadopoulos sold 10,000 shares of the business’s stock in a transaction dated Friday, September 22nd. The stock was sold at an average price of $25.40, for a total transaction of $254,000.00. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 137,302 shares of company stock worth $3,295,893. Company insiders own 5.10% of the company’s stock.

A number of hedge funds have recently added to or reduced their stakes in the stock. FMR LLC boosted its holdings in Exelixis by 2.0% during the second quarter. FMR LLC now owns 43,748,695 shares of the biotechnology company’s stock worth $1,077,530,000 after buying an additional 857,452 shares in the last quarter. Vanguard Group Inc. boosted its holdings in Exelixis by 7.2% during the second quarter. Vanguard Group Inc. now owns 25,441,964 shares of the biotechnology company’s stock worth $626,635,000 after buying an additional 1,706,893 shares in the last quarter. Matrix Capital Management Company LP boosted its holdings in Exelixis by 8.8% during the second quarter. Matrix Capital Management Company LP now owns 15,117,460 shares of the biotechnology company’s stock worth $372,343,000 after buying an additional 1,225,000 shares in the last quarter. Goldman Sachs Group Inc. boosted its holdings in Exelixis by 13.1% during the second quarter. Goldman Sachs Group Inc. now owns 7,059,232 shares of the biotechnology company’s stock worth $173,869,000 after buying an additional 818,782 shares in the last quarter. Finally, Old Mutual Global Investors UK Ltd. boosted its holdings in Exelixis by 3.1% during the second quarter. Old Mutual Global Investors UK Ltd. now owns 5,196,829 shares of the biotechnology company’s stock worth $127,997,000 after buying an additional 155,569 shares in the last quarter. 81.15% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: This news story was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this news story on another publication, it was illegally copied and reposted in violation of United States and international copyright and trademark law. The legal version of this news story can be viewed at https://www.thecerbatgem.com/2017/12/20/exelixis-exel-receives-hold-rating-from-oppenheimer.html.

Exelixis Company Profile

Exelixis, Inc is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company’s cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors.

Analyst Recommendations for Exelixis (NASDAQ:EXEL)

Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.